Population pharmacokinetics and dose–response relationships of mitoxantrone in children with acute myeloid leukaemia

British Journal of Clinical Pharmacology 2026 Open access

Read full text
Authors: Andrew M. Brandon, Hinke Siebinga, Shelby Barnett, Paul Wetherell, Pamela R. Kearns, Brenda E. S. Gibson, Nicholas B. Heaney, Owen Patrick Smith, André Baruchel, Arnaud Petit, Andrew S. Moore, Kayode Ogungbenro
+2 more Alwin D. R. Huitema, Gareth J. Veal
DOI: 10.1002/bcp.70436
Cited by: 0
References: 22

Abstract

Background Information on mitoxantrone pharmacokinetics in children is lacking and reduced dosing regimens applied to infants are supported by limited scientific rationale. The current study characterized mitoxantrone pharmacokinetics in a childhood acute myeloid leukaemia patient population and provides a data‐informed assessment of dosing. Methods A total of 282 plasma samples from 44 patients aged 0.9–17 years, receiving intravenous mitoxantrone at doses of 12 mg/m 2 /day or 0.4 mg/kg/day (patients

Fields of Study & Subjects

Pharmaceutical studies and practices Acute Lymphoblastic Leukemia research Acute Myeloid Leukemia Research

Publication details

Journal / source
British Journal of Clinical Pharmacology
Volume
92
Issue
6
Pages
1760–1770
Publication date
14 January 2026
Language
EN